Clinical Trial Imaging Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product & Services (Software and Services), By Modality (Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Positron Emission Tomography, X-Ray, Echocardiography and Other Modalities), By End-User (Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations, Academic and Government Research Institutes and Other End-Users) and Region Forecast 2020-2031

Clinical Trial Imaging Market size was valued at US$ 1.2 billion in 2024 and is expected to reach US$ 2.1 billion by 2031, growing at a significant CAGR of 8.1% from 2025-2031. By product and services, the market has been segmented into Software and Services. The Services segment is likely to be the largest and fastest-growing segment in terms of products and services in 2022 and is expected to maintain the trend in the forecasted years sue to increasing spending in R & D sector and rapid growth in the pharmaceutical sector. Based on modality, the market is segmented into Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Positron Emission Tomography, X-Ray, Echocardiography, and Other Modalities. Among these, the Computed Tomography segment is expected to have the fastest-growing market during the forecast period 2023-2029. It is attributed to increasing number of CROs, increase in research investments, and growth in pharma sector. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations, Academic and Government Research Institutes and Other End-Users. The Pharmaceutical Companies segment accounts for the largest share in 2022 and is expected to maintain the trend in the forecasted years. However, high implementation cost of imaging systems and high capital required to run clinical trials are hindering the market growth. The market is predicted to rise due to the growing biotechnology and pharmaceutical sectors, as well as rising research and development investments for generating new pharmaceuticals to treat ailments.  

Key Developments

• In May 2021, IXICO Plc. (UK) signed a contract with biopharmaceutical client IXICO to provide neuroimaging services for a Phase III clinical trial under this contract.